ArticleNature communications2016
Synthetic biology and microbioreactor platforms for programmable production of biologics at the point-of-care.
Article in Nature communications, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 89 citations in OpenAlex.
- Expression and immunoassay application of full-length recombinant antibody recognizing chlorantraniliprole using Pichia pastoris expression system.Crop health · 2026Article
- Harnessing engineered cyanobacteria for next-generation therapeutics.Archives of microbiology · 2026Review
- Production of Biopharmaceutical Proteins from Scallop Hemocytes as a Bioreactor Using Improved Transfection Conditions.Marine biotechnology (New York, N.Y.) · 2026Article
- Systematic Review on the Role of Microfluidic Platforms in Advancing Scalable and Precise Microbial Bioprocessing.Engineering in life sciences · 2025Review
- Synthetic biology for space exploration.NPJ microgravity · 2025Review
- Glycosylation of Structured Protein Domains in Cell-Free Reaction Environments.ACS synthetic biology · 2025Article
- Transcriptome analysis reveals methanol metabolism variations for the growth damage caused by overexpression of chimeric transactivators inSynthetic and systems biotechnology · 2025Article
- Designing strong inducible synthetic promoters in yeasts.Nature communications · 2024Article
- A high-density microfluidic bioreactor for the automated manufacturing of CAR T cells.Nature biomedical engineering · 2024Article
- Recombinant production of Paenibacillus wynnii β-galactosidase with Komagataella phaffii.Microbial cell factories · 2024Article
- Promoter engineering enables precise metabolic regulation towards efficient β-elemene production inSynthetic and systems biotechnology · 2024Article
- Article
- Rapid biosynthesis of glycoprotein therapeutics and vaccines from freeze-dried bacterial cell lysates.Nature protocols · 2023Review
- On-demand biomanufacturing through synthetic biology approach.Materials today. Bio · 2023Article
- Cloning, expression, and molecular modification of glycoside hydrolase family 5 genes from Thermoascus aurantiacus.PloS one · 2023Article
- A programmable high-expression yeast platform responsive to user-defined signals.Science advances · 2022Article
- Biotechnology Applications of Cell-Free Expression Systems.Life (Basel, Switzerland) · 2021Review
- High-throughput 5' UTR engineering for enhanced protein production in non-viral gene therapies.Nature communications · 2021Article
- A genome-scale yeast library with inducible expression of individual genes.Molecular systems biology · 2021Article
- Engineered yeast genomes accurately assembled from pure and mixed samples.Nature communications · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Current biopharmaceutical manufacturing systems are not compatible with portable or distributed production of biologics, as they typically require the development of single biologic-producing cell lines followed by their cultivation at very large scales. Therefore, it remains challenging to treat patients in short time frames, especially in remote locations with limited infrastructure. To overcome these barriers, we developed a platform using genetically engineered Pichia pastoris strains designed to secrete multiple proteins on programmable cues in an integrated, benchtop, millilitre-scale microfluidic device. We use this platform for rapid and switchable production of two biologics from a single yeast strain as specified by the operator. Our results demonstrate selectable and near-single-dose production of these biologics in <24 h with limited infrastructure requirements. We envision that combining this system with analytical, purification and polishing technologies could lead to a small-scale, portable and fully integrated personal biomanufacturing platform that could advance disease treatment at point-of-care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.